Percentages of positive cores, cancer length and Gleason grade 4/5 cancer in systematic sextant biopsy are all predictive of adverse pathology and biochemical failure after radical prostatectomy

International Journal of Urology

Volumn 14, Issue 8, 2007, Pages 713-718

  Suekane, Shigetaka ^a   Noguchi, Masanori ^a   Nakashima, Osamu ^a   Yamada, Satoko ^a   Kojiro, Masamichi ^a   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Prostate biopsy; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CHEMICAL ANALYSIS; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 34547627659     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01809.x     Document Type: Article

References (21)

1. Sun L, Gancarezyk K, Paquette EL et al. Introduction to Department of defense center for prostate disease research multicenter national prostate cancer database, and analysis of changes in the PSA-era. Urol. Oncol. 2001 6 : 203.
2. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997 277 : 1445 51.
3. Kattan MW, Eastham JA, Stapleton EN, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl. Cancer Inst. 1998 90 : 766 71.
4. D'Amico AV, Whittington R, Malkowicz SB et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J. Clin. Oncol. 2000 18 : 1164 72.
5. Presti JC Jr, Shinohara K, Bacchetti P, Tigrani V, Bhargava V. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998 52 : 1079 84.
6. Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score. J. Urol. 2002 167 : 516 20.
7. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol. 1989 142 : 71 5.
8. Noguchi M, Stamey TA, McNeal JE, Yemoto CE. Assessment of morphometric measurements of prostate cancer Volume. Cancer 2000 89 : 1056 64.
9. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J. Urol. 1998 160 : 2407 11.
10. Noguchi M, Stamey TA, McNeal JE, Yemoto CEM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J. Urol. 2001 166 : 104 10.
11. Freedland SJ, Aronson WJ, Terris MK et al. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy. Cancer 2003 98 : 2344 50.
12. San Francisco IF, Regan MM, Olumi AF, DeWolf WC. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J. Urol. 2004 171 : 1492 9.
13. Sebo TJ, Bock BJ, Cheville JC, Lohse C, Wallan P, Zinke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and Volume at radical prostatectomy. J. Urol. 2000 163 : 174 8.
14. Humphrey PA, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathological features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995 75 : 1842 9.
15. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG. Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J. Clin. Onc 2000 18 : 2362 8.
16. Freedland SJ, Aronson WJ, Csathy GS et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the search database. Urology 2003 61 : 742 7.
17. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993 270 : 948 54.
18. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000 163 : 163 7.
19. Eskew LA, Bare RL, McCulloch DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol. 1997 157 : 199 203.
20. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999 281 : 1395 400.
21. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6versus 12 prostate biopsy cores: impact on cancer detection. J. Urol. 2000 164 : 388 92.